Study S000572

Liraglutide 3.0mg/d for the Treatment of Binge Eating Disorder

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)Informed Consent Form (PDF)

Registration

Registration: NCT03279731
Acronym: BELIEVE
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: TERMINATED
Enrollment: 36
Start: 2017-09-29
Primary completion: 2019-09-30
Lead sponsor: Kelly Allison
Conditions: Binge-Eating Disorder
Interventions: DRUG:Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml; DRUG:Placebo
Results posted: TRUE
Individual participant data sharing: NO

Registered primary outcomes

Binge Episodes [baseline and 17 weeks (or last observation carried forward)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.